Myung In Pharm Co

Myung In Pharm Co OCF Margin

The Operating Cash Flow Margin of Myung In Pharm Co (317450.KS) as of Nov 18, 2026 is 28.39 %. In the previous year, Operating Cash Flow Margin was 31.37 % — a change of -9.50% (lower).

OCF Margin

28.39 %

YoY

-9.50%

Last updated:

Operating Cash Flow Margin of Myung In Pharm Co is 2025 28.39 % . Operating Cash Flow Margin of Myung In Pharm Co was 2024 31.37 % . It decreases by -9.50% lower compared to the previous year.

The Myung In Pharm Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2023
31.37 KRW
Jan 1, 2025
28.39 KRW
The Myung In Pharm Co OCF Margin history
YEAROCF MarginYoY
28.39 %-9.50%
31.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Myung In Pharm Co Stock analysis

What does Myung In Pharm Co do? Myung In Pharm Co., Ltd. generates revenue through the manufacture and sale of prescription drugs for neurology and psychiatry, including stroke and Parkinson’s disease treatments, schizophrenia, and depression therapies. The company primarily targets domestic and overseas markets, distributing its products under its own brand for neurological and psychiatric conditions. General pharmaceuticals such as dental, oral, digestive system treatments, and other related products form additional revenue streams within its domestic and international sales channels. The firm focuses on prescription drug segments, with key products addressing stroke, Parkinson’s disease, schizophrenia, and depression. These treatments are sold directly to healthcare providers and pharmacies in both domestic and overseas markets. The company also offers general pharmaceuticals like dental and oral treatments, alongside digestive system therapies, contributing to its diversified product portfolio across multiple therapeutic areas. Myung In Pharm’s business model relies on selling branded prescription medications for specific neurological and psychiatric conditions, alongside general pharmaceuticals. Its domestic and overseas market presence ensures consistent revenue from both regional and global healthcare sectors, with no additional details on specific customer segments or pricing strategies disclosed in the provided description. Myung In Pharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myung In Pharm Co stock

Operating Cash Flow Margin of Myung In Pharm Co is 28.39 % in 2025.

Operating Cash Flow Margin of Myung In Pharm Co changed from 31.37 % to 28.39 %, representing a -9.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Myung In Pharm Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Myung In Pharm Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Myung In Pharm Co

All Key Metrics — Myung In Pharm Co